Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Olaszország3. fázis

Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections

A legfontosabb adatok

Ki végzi
Tobias Feuchtinger
Hol
Rome (Olaszország)A helyszín megnézéseMég 5 másik országban, 20 helyszínen
Állapot
Toboroz
Fázis
3. fázis
Résztvevők
149 fő, tervezett
Kezdés
2019. aug. 27.
Várható befejezés
2028. szept.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Multivirus (CMV, EBV, AdV)-specific T cells
A regiszteradat frissítve
2025. július 18.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for children and adults who had a donor stem cell transplant and now have a CMV, EBV or AdV virus infection. The infection has not improved with standard antiviral medicine.

Életkor
Older than 2 months; children and adults can join.
Nem
All sexes can join.
A betegség stádiuma
A new or returning CMV, EBV or AdV infection after a stem cell transplant from a donor. There is no time limit after the transplant. The infection has not responded to standard antiviral treatment for two weeks.
Korábbi kezelés
People must have had a donor (allogeneic) stem cell transplant. They must have had standard antiviral treatment for two weeks without enough effect.
Biomarker vagy leletérték
A blood PCR test must show the virus amount did not drop, or dropped by less than 1log, over two weeks. The original stem cell donor must be available and have immunity to the virus causing the infection.

A részvétel fő kizáró okai

  • Acute graft-versus-host disease above grade II, or extensive chronic graft-versus-host disease
  • Taking steroids above 1 mg/kg body weight Prednisone equivalent at screening
  • Very poor general health (Karnofsky or Lansky score of 30% or less)
  • Known HIV infection
  • Pregnant or breast-feeding women

A regiszter feltételei, szó szerint

Mind a 15 feltétel megnézéseKevesebb

Ki vehet részt

  • Adult or paediatric patients (> 2 months of age) after allogeneic stem cell transplantation (SCT) (no time restrictions apply) suffering from new or reactivated CMV or EBV or AdV infection refractory to standard antiviral treatment for two weeks (defined as no decrease or insignificant decrease of less than 1log in viral load over two weeks) as confirmed by quantitative blood PCR analysis
  • Original HSCT-donor available with an immune response at least to the virus causing the therapy-refractory (=underlying) infection
  • Written informed consent given (patient or legal representative) prior to any study-related procedures

Ki nem vehet részt

  • Patient receiving steroids (>1 mg/kg BW Prednisone equivalent) at Screening
  • Concomitant enrolment in another clinical trial interfering with the endpoints of this study
  • Any medical condition which could compromise participation in the study according to the investigator's assessment
  • Progression of underlying disease (disease that has led to the indication of HSCT, e.g. leukaemia) that will limit the life expectance below the duration of the study
  • Known hypersensitivity to iron dextran
  • Therapeutic donor lymphocyte infusion (DLI) from 4 weeks prior to IMP infusion until 8 weeks post IMP infusion. Prescheduled prophylactic DLI ≤3x105 T cells/kg BW in case of T-cell depleted HSCT is not considered an exclusion criterion
  • Known HIV infection. In case patients do not have a negative HIV test performed within 6 months before enrolment in the study, HIV negativity has to be confirmed by a negative laboratory test
  • Female patient who is pregnant or breast-feeding. Female patient of child-bearing potential (i.e. post menarche and not surgically sterilized) or male patient of reproductive potential not willing to use an effective method of birth control from Screening until the last follow-up visit (FU6, Visit 8); Note: Women of childbearing potential must have a negative serum pregnancy test at study entry ≤7 days before IMP administration on Day 0. Acceptable birth control methods are hormonal oral contraceptive ('pill'), contraceptive injection or patch, intrauterine pessar or the combination of two barrier methods. The combination of female and male condomes is NOT acceptable. If the male partner is sterilized, no further contraceptive is required. Women of post-menopausal status (no menses for 12 months without an alternative medical cause) are also not required to use contraceptives during the study
  • Patient with organ dysfunction or failure as determined by Karnofsky (patients >16 years) or Lansky (patients ≤16 years) score ≤30%
  • Patient with acute GvHD > grade II or extensive chronic GvHD at the time of IMP transfer
  • Second line or experimental antiviral treatment other than Ganciclovir/Valganciclovir, Foscarnet, Cidofovir and Rituximab until 8 weeks after IMP Infusion or prophylactic Treatment other than Aciclovir or Letermovir throughout the study except approved by sponsor
  • Patients unwilling or unable to comply with the protocol or unable to give informed consent

Helyszínek itt: Olaszország

Még 5 másik országban, 20 helyszínen

  • Bambino Gesu Childrens HospitalRome, OlaszországRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Haematopoietic stem cell transplantation (HSCT) can expose patients to a transient but marked immunosuppression, during which viral infections are an important cause of morbidity and mortality. Adoptive transfer of virus-specific T cells is an attractive approach to restore protective T-cell immunity in patients with refractory viral infections after allogeneic HSCT. The aim of this Phase III trial is to confirm efficacy of this treatment in children and adults.

A vizsgálat 2 csoportja

  • Multivirus (CMV, EBV, AdV)-specific T cellsA vizsgált kezelés

    Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of Cytomegalovirus, Adenovirus and Epstein-Barr Virus Max dose: * HLA-matched (8/8) donors: 1.0 x 10e5 T cells/kg recipient BW * HLA-mismatched donors: 2.5 x 10e4 T cells/kg recipient BW Min. dose: \- 10 T cells/kg recipient BW

  • Sodium chloridePlacebo, összehasonlításként

    Suspension of multivirus-specific T cells in 20 mL of 0.9% NaCl + 0.5% HSA

    Kezelés: Multivirus (CMV, EBV, AdV)-specific T cells

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
Treatment of Chemo-refractory Viral Infections After Allogeneic Stem Cell Transplantation With Multispecific T Cells Against CMV, EBV and AdV: A Phase III, Prospective, Multicentre Clinical Trial
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
A regiszteradat frissítve
2025. július 18.